Working Capital Management Seizes Priority in North American and European Pharma Industry
Efforts to improve working capital efficiency are becoming entrenched in the growth strategy of pharmaceutical firms in North America and Europe. The realization is that an effective working capital management will ease the difficulties caused by low sales, pricing pressures and patent cliffs. Big pharma companies expect to invest in optimizing working capital efficiency to bolster returns.
Analysis from Frost & Sullivan, Working Capital Management in the North American and European Pharmaceutical Industry, reveals companies in the US effectively managed to reduce the cash conversion cycle by 44.2% between 2012 and 2013. European companies were not as successful, managing to reduce the cash conversion cycle by 26.2% between 2012 and 2013. The cash conversion cycle is an indicator of working capital efficiency.
“Business models in the North American and European pharmaceutical industry are evolving; placing emphasis on achieving working capital efficiency by focusing on outsourced manufacturing and new market entry,” said Frost & Sullivan Senior Research Analyst Saneesh Edacherian.
The following issues highlight the importance of effective working capital management.
• Decreasing Profitability: Global economic slowdowns, expiring blockbuster drug patents, intensifying competition and lowering public spending on drugs affect the profitability of participants in the pharma and biotech industry, spurring the need for effective working capital management.
• Fizzling Innovation Model: Leading pharmaceutical manufacturers are facing a twofold crisis. The number of blockbuster drugs about to lose their patents is alarmingly high, and pipelines are empty. With no new sources of revenue emerging, cutting costs through working capital management is crucial to optimize expenses.
• Price Premium Pressure: Strict regulations and diverse healthcare models across geographies are compelling drug companies to cut costs, making working capital management a necessary ingredient in their strategic mix to sustain profits.
• Access to New Markets: Working capital management will gain further significance as major market participants in North America and Europe look to developing economies for merger and acquisition opportunities.
“Chinese, Indian and Latin American countries constitute large unexplored markets for drug makers,” concluded Edacherian. “The development of research centres and manufacturing plants will require adept working capital management, and a surefire way to ensure a smooth entry into these regions.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance